Evidence map›Paper›PMID 41712039›Full record

ArticleMedical oncology (Northwood, London, England)2026

Maleimide-substituted 1,4-naphthoquinone flaviolin mimetic (FM

Samriti Saklani, Ashish Sahu, Akhil Karandikar, Vaidehi Bhavsar, Santosh Kumar Behera, Satyasheel Sharma, Ravindra Taware

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samriti SaklaniDepartment of Natural Products, National Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India.
Ashish SahuDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India.
Akhil KarandikarDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India.
Vaidehi BhavsarDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India.
Santosh Kumar BeheraNational Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India.
Satyasheel SharmaDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India. sharma.satyasheel@gmail.com.
Ravindra TawareDepartment of Natural Products, National Institute of Pharmaceutical Education and Research-Ahmedabad, Palaj, Gandhinagar, 382355, Gujarat, India. ravindra.taware@niperahm.res.in.

Funding

Science and Engineering Research Board EEQ/2022/000309
6 · The paper itself

Abstract

Effective treatment for multiple myeloma remains a significant clinical challenge due to multidrug resistance and the side effects of current chemotherapies, indicating the need for new interventions. Flaviolin, a 1,4-naphthoquinone derivative isolated from Aspergillus sp., possesses favourable cytotoxic activity against the RPMI-8226 multiple myeloma cell line. This study provides the first in-vitro biological evidence of its cytotoxicity against multiple myeloma by inducing S-phase arrest and apoptosis. We further investigated the structure-activity relationship of 16 flaviolin mimetics. The results showed that Flaviolin mimetic FM

Indexed as

Antineoplastic AgentsApoptosisMitochondriaMultiple MyelomaNaphthoquinonesS Phase Cell Cycle CheckpointsCell Line, TumorHumansS PhaseStructure-Activity Relationship1,4-naphthoquinoneAntineoplastic AgentsNaphthoquinonesApoptosisCell cycleDockingFlaviolinMultiple myelomaNetwork pharmacologyProteomics

Identifiers

PMID41712039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.